CONNECT
Close

Thailand
19 Soi Udomsuk 37, Bangkok 10260, Thailand

+662 361 8110

France
41 Cours de la Liberté 69003 Lyon Cedex 03

[email protected]

An-Alternative-to-Pertussis-Combination-Vaccines-for-Booster-Use

An Alternative to Pertussis Combination Vaccines for Booster Use

An Alternative to Pertussis Combination Vaccines for Booster Use Combination vaccines containing pertussis, tetanus, and diphtheria antigens have played a central role in pertussis prevention for many years. However, not all individuals requiring pertussis booster vaccination need repeated immunisation against tetanus…

Read More
Maternal-Immunisation-and-Passive-Protection-of-Newborns

Maternal Immunisation and Passive Protection of Newborns

Maternal Immunisation and Passive Protection of Newborns Maternal vaccination is a proven way to protect young babies from pertussis (whooping cough) during their first months of life, before they finish their primary vaccination series. BioNet’s pertussis‑only vaccine is approved for use…

Read More
bacteria-05022026-02

A Focused Strategy Against Pertussis Toxin

A Focused Strategy Against Pertussis Toxin Pertussis toxin is a central virulence factor of Bordetella pertussis and is closely associated with the severe clinical manifestations of whooping cough. The scientific rationale for BioNet’s pertussis-only vaccine is based on inducing immune responses…

Read More
European Commission Grants EU Marketing Authorisation for a New Pertussis-Only Vaccine

Pertussis-Only Booster Vaccine Receives EU Marketing Authorisation

Pertussis-Only Booster Vaccine Receives EU Marketing Authorisation For many individuals, protection against pertussis remains important, while booster vaccination against tetanus and diphtheria may not always be required at the same time. BioNet has developed a pertussis-only vaccine that has received Marketing…

Read More
Clinical Evidence Supporting EU Authorisation

Clinical Evidence Supporting EU Authorisation

Clinical Evidence Supporting EU Authorisation The Marketing Authorisation of BioNet’s pertussis-only vaccine is supported by a comprehensive clinical development programme reviewed by the Committee for Medicinal Products for Human Use (CHMP). The assessment included data from three main randomised controlled clinical…

Read More
An-EU-Authorised-Pertussis-Only-Booster-Vaccine-for-Healthcare-Professionals

An EU-Authorised Pertussis-Only Booster Vaccine for Healthcare Professionals

EU-Authorised Pertussis-Only Booster Vaccine for Healthcare Professionals Healthcare professionals are among the population groups with increased potential exposure to pertussis. In many healthcare settings, booster vaccination is recommended at regular intervals to help maintain protection and reduce the risk of transmission…

Read More
EU-Authorised-Pertussis-Booster-Vaccination-for-Teenagers

EU-Authorised Pertussis Booster Vaccination for Teenagers

EU-Authorised Pertussis Booster Vaccination for Teenagers Teenagers play an important role in the transmission dynamics of pertussis. As immunity acquired through early childhood vaccination gradually wanes, adolescents may become susceptible again. In this age group, pertussis infection can present with mild…

Read More
EU-GMP-certification

The European Commission Grants Marketing Authorisation for a First-of-its-Kind Pertussis-Only Vaccine

The European Commission Grants Marketing Authorisation for a First-of-its-Kind Pertussis-Only Vaccine for Vaccination of Teenagers, Adults and Pregnant Women in the European Union Europeans in the European Union (EU) may soon have the choice to get vaccinated against whooping cough with…

Read More
EU-GMP-certification

BioNet Achieves EU-GMP Certification for its Pertussis Vaccine Manufacturing

BioNet Achieves EU-GMP Certification for its Pertussis Vaccine Manufacturing Lyon, France – October 29, 2025, BioNet today announced it has received European Union Good Manufacturing Practice (EU-GMP) certification, an internationally recognized benchmark of pharmaceutical quality and compliance, to produce its acellular…

Read More
Poster-Press Conference-PreBoost-22(00)-04-2025

Clinical Study on Reduced-Dose Pertussis Vaccine in Thailand

Clinical Study on Reduced-Dose Pertussis Vaccine in Thailand In collaboration with Faculty of Medicine, Chulalongkorn University, BioNet has advanced a clinical study on a next-generation pertussis vaccine, featuring a reduced-dose recombinant acellular pertussis formulation—from 5 μg to 2 μg while maintaining…

Read More